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Abstract: A virulent recombinant HSV lacking the diploid 134.5 gene (134.5) have been 
investigated over the last two decades both for anti-tumor therapy and as vaccine vectors. 
The first generation vectors, while safe, are incapable of sustained replication in the 
majority of treated patients. An interferon inducible host antiviral kinase, protein kinase R 
(PKR), limits late viral protein synthesis and replication of 134.5 viruses. This review 
describes the development of new 134.5 vectors, through serial passage selection and 
direct viral genome engineering, which demonstrate selective PKR evasion in targeted cells 
and improved viral replication without restoring neurovirulence. 
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1. Introduction  
Serial passage is a time-honored viral laboratory method that has been used to select progeny with 
attenuating mutations (e.g. OKA vaccine strain from varicella zoster virus). In recent years, serial 
passaging has been used as a method to identify secondary mutations in attenuated HSV oncolytic 
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vectors that mediate improved viral replication and anti-tumor activity. Additional uses for the serial 
passaging techniqueinclude: i) the testing of genetic stability of biologic therapeutics and potential 
pathogenic mutations; ii) identification of cryptic gene functions that may have served evolutionarily 
distant functions for the virus; and iii) to identify antiviral escape mutations, that can then provide 
leads to improved drug design. 
This review focuses on the interferon-induced, innate antiviral response triggered during viral 
transcription that limits protein synthesis initiation in the infected cell. In addition to discussing the 
protein product encoded by the HSV 134.5 gene that counters this host antiviral response, the review 
also describes how mutant viruses lacking the 134.5 gene (134.5) have been studied as vaccine and 
anti-tumor therapies because of their safety in humans. While these vectors are safe, their limited late 
viral protein synthesis and diminished replication limit their efficacy. Serial passage of 134.5 
recombinants has been used to identify whether compensatory mutations improve viral replication or 
the anti-tumor properties of the 134.5 mutants. Current efforts to improve these vectors’ replication 
are now focused upon engineering a new generation of HSV recombinants based on the earlier serial 
passage experiments. 
2. PKR Innate Antiviral Response 
Eukaryotic cells contain innate defenses that target viral infection  [1]. A principal component of 
this defense is protein kinase R (PKR), which limits viral gene expression and replication in human 
cells (summarized in Figure 1)  [2]. 
Low levels of this evolutionarily conserved, interferon-inducible kinase are present in unstressed 
cells. However, its production is induced by type I interferons or double-stranded RNA (dsRNA) 
produced during viral infection  [1]. Upon binding dsRNA, the kinase activates and phosphorylates 
itself as well as cellular proteins involved in the antiviral response. The best characterized of the 
substrates is the α subunit of eukaryotic translation initiation factor 2 (eIF-2)  [3,4]. Phosphorylation 
of eIF-2 prevents recycling of a critical translation initiation factor, thus limiting viral and cellular 
protein synthesis in the infected cell  [2].  
In addition to its antiviral functions, the PKR-mediated host protein shutoff response is also 
involved in cellular homeostasis. Consequently, second messenger signaling pathways and PKR 
modulate one another’s activity in the cell. These pathways can block PKR activation during periods 
of cellular stress or when the cell is actively replicating. For example, upregulation of mitogen-
activated protein kinase (MAPK) activity in the cell (mediated by a component of this pathway, MEK) 
blocks PKR activation during growth factor stimulation  [5,6]. Likewise, PKR has also been shown to 
act as a signal integration point between signaling pathways  [7]. While regulation of protein synthesis 
initiation is the best characterized of the PKR antiviral functions, the kinase also modulates other 
cellular functions, including: bulk protein degradation in the cell (also called autophagy), RNA 
transcription, and signal transduction in the cell  [5,8-10]. Viruses 2009, 1                                       
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Figure 1. Summary of PKR mediated protein shutoff and HSV ICP34.5 defense. (1) HSV 
entry, gene expression, 2) complementary transcripts anneal and form stable dsRNA 3) PKR 
binds dsRNA resulting in activation and autophosphorylation, 4) activated PKR selectively 
phosphorylates eIF-2inhibiting protein translation, 5) HSV produces ICP34.5 which 6) forms 
a multiprotein complex with the host phosphatase PP1 7) and dephosphorylates eIF2. 8) An 
example of pulse labeling study showing abundant radioactive methionine incorporation in 
uninfected (M) and wild-type HSV-1-infected (F) proteins at 12hpi but decreased incorporation 
in ICP34.5(-) infected cells ().  
 
 
3. The HSV-1 134.5 Gene 
The HSV-1 134.5 gene encodes a multifunctional protein called ICP34.5  [11,12]. One function, 
encoded within the 3’ gene domain, blocks host PKR-mediated protein shutoff during infection thus 
allowing continued late viral protein synthesis in infected cells  [13]. During infection, wild-type HSV-
1 produces complementary mRNA transcripts that anneal, forming stable dsRNA, which triggers the 
dimerization and activation of dsRNA-activated host PKR. The ICP34.5 overcomes this PKR-
mediated host protein shutoff by binding and recruiting a host phosphatase that specifically 
dephosphorylates eIF-2, allowing continued viral protein synthesis (hereafter referred to as the HSV 
wild-type protein synthesis phenotype) in the infected cell  (summarized in Figure 1)  [14,15].  
Recombinant viruses that lack the 134.5 gene, (134.5 HSVs) are incapable of maintaining eIF-2 
in an unphosphorylated form and therefore are unable to maintain protein synthesis in the infected 
cell  [16]. Cessation of protein synthesis occurs at the onset of viral DNA synthesis late in infection, 
essentially eliminating bulk synthesis of viral structural proteins necessary for viral capsid 
formation  [16]. In addition to structural proteins, viral encapsidation, envelopment and maturation are 
necessary for efficient viral replication. There are examples of 134.5 mutants that are capable of late Viruses 2009, 1                                       
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viral protein synthesis but that cannot negotiate the other steps necessary for viral replication  [17]. 
Evidence suggests that in addition to protein translation, other cellular processes are disrupted in 
134.5 infected cells that are critical for viral egress. Consequently, 134.5 HSV replicate 
inefficiently and produce fewer progeny virions in cells with intact PKR pathways  [18]. While the 
134.5 gene product does not interrupt IFN signaling in the infected cell as has been described with the 
HSV UL13 and UL39 gene products, ICP34.5 is critical for HSV evasion of the IFN inducible gene 
product, PKR. Consequently, 134.5 viruses are highly sensitive to Type I IFN and replicate poorly in 
vivo or in IFN treated cells  [19,20]. Restoration of the protein synthesis function allows 134.5 HSV 
to replicate efficiently in the presence of the type l IFN ( or  interferon) response  [17]. 
The 134.5 gene also encodes a second function, neurovirulence, enabling efficient viral replication 
in post-mitotic neuronal cells  [12-14,21]. The neurovirulence and protein synthesis functions encoded 
by the 134.5 gene are discrete and separable. Late viral protein synthesis can be selectively restored 
without restoring wild-type neurovirulence  [17,22,23]. The 134.5 HSV are incapable of efficient 
replication after direct inoculation in the CNS and do not cause encephalitis  [12]. As such, 134.5 
HSV vectors have been developed as anti-tumor agents for CNS-based malignancies. Whereas 50-100 
PFU of wildtype HSV will lead to encephalitis and death in half of the mice inoculated intracerebrally, 
more than 1 x 10
7 PFU are required to produce encephalitis and death with a 134.5 HSV 
recombinant   [12]. Finally, the 134.5 gene also allows HSV-1 to block autophagy in infected 
cells  [24]. This function contributes to HSV neurovirulence, maps within the 5’ domain of the gene 
and allows binding and sequestering of beclin-1, a host protein necessary for autophagosome 
formation  [24]. 
4. 134.5 HSV as Oncolytic Vectors 
Genetically modified HSV are attractive as replication-competent, oncolytic vectors as well as 
vaccine vectors for a number of reasons: 1) procedures for constructing novel HSV are well 
established; 2) genetic modifications (insertions or deletions) do not significantly affect virus 
replication; 3) considerable experience with the biology of HSV and its behavior in humans and 
nonhuman primates exists; and 4) modified herpesviruses retain sensitivity to standard antiviral drug 
therapy as a “built-in” safety feature  [25-27]. Deletion of the HSV-1 neurovirulence gene, 134.5, 
allows the safe administration of recombinant vectors intracranially (for brain tumor therapy) or 
systemically (for peripheral tumors or as a vaccine vector).  
In addition to inhibiting protein synthesis initiation, other viral functions are inhibited as a 
consequence of this deletional mutation. The 134.5 mutants also demonstrate changes in 
glycoprotein processing Figure 2). The HSV134.5 gene product differs in amino acid sequence 
between viral strains. Adoptive transfer studies have shown that these ICP34.5 amino acid differences 
affect glycoprotein processing and plaque phenotype in cell culture  [28,29]. In viruses lacking the 
134.5 gene, the differences in glycoprotein processing are even more dramatic. Immunostaining 
studies show that gD in the 134.5 infected cells exist in a single form after separation using 
denaturing conditions. In contrast, viruses capable of PKR evasion and late viral protein synthesis 
exhibit multiple slower migratory forms of the glycoprotein indicative of further glycoprotein 
processing. In figure 2 the chimeric HSV, C130, which contains the HCMV PKR-evasion gene TRS1, Viruses 2009, 1                                       
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contains multiple forms of glycoprotein D, similar to that observed for wild-type HSV. Confocal 
immunofluorescence microscopy further demonstrates differences in glycoprotein trafficking in the 
infected cell. In tumor cells infected with recombinants capable of late viral protein synthesis, gD 
accumulates within the trans golgi network (TGN) and late endosomal compartment based upon gD 
and AP-1 staining and colocalization. In contrast, gD expressed in the 134.5 infected cells does not 
localize with adaptor protein complex 1 (AP-1) in the TGN. There are also fundamental differences in 
the appearance of the TGN. In the 134.5 infected cells, the TGN appears disrupted throughout the 
cytoplasm and does not exhibit the more structured perinuclear aggregates seen in cells capable of 
continued protein synthesis. The 134.5 recombinants also exhibit differences in protein degradation 
or autophagy within the infected cell   [8]. Improved protein production and processing may may 
enhance the antitumor capabilities of 134.5 mutants either directly (improved antigen expression and 
replication) or indirectly by improving the expression and processing of foreign gene inserts in 
recombinants for gene therapy applications. 
Figure 2. Glycoprotein processing differences between 134.5 and HSVs capable of PKR 
evasion and late viral protein synthesis. A) Autoradiograph showing radiolabeled viral 
proteins produced in infected malignant glioma cells. Viruses capable of PKR evasion 
(HSV-1 and the chimeric HSV, C130 [discussed in detail in section 6.4]) produce abundant 
35S-Methionine-radiolabeled proteins at 12hpi. In contrast, the 134.5 recombinants 
(C101) and the Chimeric HSV repair virus (C131) have reduced protein synthesis. B) 
Immunostaining using Ig anti-glycoprotein D (clone H170: SC-69802 Santa Cruz 
Biotechnology) shows abundant late gene accumulation in the HSV-1 and chimeric HSV 
(C130) samples as well as multiple migratory gD forms (arrows) indicative of glycoprotein 
processing in the infected cells. C) Confocal immunofluorescence imaging shows gD 
(green) distribution in 134.5 (left upper panel) and C130 (right upper panel) -infected 
U87-MG cells and colocalization with the Transgolgi network marker AP-1 (Sigma). Co-
localization detected (yellow) in the chimeric HSV infected samples (lower right panel) but 
not in the 134.5 infected cells. 
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In addition to protein processing recent studies also show that the 134.5 gene product also inhibits 
IFN response in the cell. ICP34.5 targets the ability of the TANK-binding kinase 1 (TBK1) to activate 
an antiviral response through interferon regulatory factor 3 (IRF3) and cytokine expression.  [30] 
Phosphorylation and transnuclear translocation of IRF3 as well as expression of downstream genes 
functioning in antiviral responses are thereby inhibited by the 134.5 protein product. Suppression of 
the interferon signaling pathway has consistently been shown to be a major mode of the interaction of 
HSV with the innate immune system, and its interaction with TBK1 appears to be a novel but critical 
mechanism to ensure successful and productive HSV infection. 
 
5. Serial Passage and Escape Mutations 
5.1. In vitro passage 
Attenuated 134.5 recombinants have been engineered for use as antitumor agents. While the 
vectors are safe and replicate in mitotically active cells, they do not exhibit robust replication. This 
limited replication and spread is one factor thought to limit their efficacy in vivo. Studies have 
described acquisition of mutations that overcome certain limitations of the ICP34.5-negative status of 
attenuated HSV-1  [31]. Mohr and Gluzman reported selection of the SUP-1 mutant after passage of 
the 134.5 SPBg5e (derived from the Patton HSV-1 strain) in the nonpermissive SK-N-SH human 
neuroblastoma cell line in vitro  [31]. SUP-1 acquired a deletion in the US12 region, resulting in two 
fundamental changes in the viral phenotype: 1) deletion of US12 results results in greater MHC I 
expression (as discussed in detail in Section 6), and 2) earlier expression of the US11 gene  [31,32]. 
Later studies using engineered recombinants and recombinant expressed US11 protein in biochemical 
studies demonstrated that this kinetic shift in US11 expression enabled viral evasion of PKR and late 
viral protein synthesis  [33]. The US11 product, although capable of precluding activated PKR from 
phosphorylating its target substrate eIF-2, was much more effective and at lower concentrations at 
blocking the activation of PKR by dsRNA  [32]. Ultimately these escape mutations produced progeny 
virus capable of continued viral protein translation in infected SK-N-SH cells  [33]. Mohr’s mutant 
SUP-1, while it had a protein synthesis phenotype similar to that of wild-type HSV-1, retained the 
neurovirulence profile of its 134.5 parent (LD50>6 x10
5); however, it was engineered in a more 
neurovirulent strain of HSV-1 which limited maximal LD50 testing  [34,35]. 
R3616, derived from the parent HSV-1 (F) strain, was also sequentially passaged in two different 
cell lines that restricted 134.5 late viral protein synthesis. Serial passage in HeLa cells produced 
progeny virus with no compensatory mutations   [18]. The parent passage 0 virus and the virus 
recovered after 8 serial infections in the HeLa cell line both had a 134.5 phenotype. It was concluded 
that because 134.5 recombinants are capable of modest viral replication in HeLa cells that the 
selection was not sufficiently rigorous to provide compensatory mutant viruses with a selective 
advantage. Serial passage in SK-N-SH cells produced progeny that, like SUP-1, were capable of 
blocking the protein kinase R (PKR)-induced shutoff of protein synthesis   [18]. Unlike SUP-1, 
however, these mutations mapped outside of the US10-12 domain, and at least one isolate had acquired 
a partially restored neurovirulence profile  [18].  Viruses 2009, 1                                       
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5.2. In vivo passage 
In vivo passage has also been used to develop improved 134.5 anti-tumor activity. M002, a 
134.5 recombinant that expresses murine IL-12, was sequentially passaged in flank tumors of the 
HSV-1 resistant D54-MG cell line. This study was based on the assumption that the virus would, 
through selective pressure incurred by the tumor microenvironment, acquire mutations allowing for 
more efficient replication in the resistant tumor cell line  [36]. M002 and its parent virus, R3659 were 
each sequentially passaged in D54-MG tumor cells in vivo in flank tumors, and in vitro in cell 
culture   [36]. In vitro passage in tissue culture selected for mutants similar to the passaged virus 
described originally by Mohr. The progeny virus expressed US11 earlier in infection, exhibited a wild-
type protein synthesis phenotype, and was found in in vivo studies to partially restore HSV 
neurotoxicity (LD50 - 5.1x10
5 – 1.67x10
6). Interestingly, these secondary mutations did not improve 
the anti-tumor activity of the 134.5 recombinants. Tumor-bearing animals had similar survival rates 
irrespective of whether they were administered the parent virus or a serially passaged virus capable of 
late viral protein synthesis  [36].  
In contrast, in vivo passage in D54 flank tumors selected for second site 134.5 mutants with 
different compensatory mutations and a different phenotype. In vivo passaged viruses demonstrated 
decreased neurovirulence as compared to the non-passaged parent viruses and resulted in significantly 
improved survival of tumor-bearing mice in two separate murine experimental brain tumor models: 
human D54-MG intracranial xenografts in SCID mice and murine Neuro-2a neuroblastoma syngeneic 
tumors in A/J mice. The in vivo passaged virus retained strict 2 kinetic expression of the US11 gene 
and 134.5 protein shutoff phenotype. However, the recombinants were more effective in their anti-
tumor activity   [36]. In contrast to specifically engineered constructs, it can be more difficult to 
identify the particular mutation(s) responsible for the phenotypic changes seen in passaged viruses, and 
therefore, their interaction with the host environment more elusive to explain. Currently, the 
compensatory mutation responsible for this change has not been mapped, re-emphasizing the primary 
limitation of the serial passage process. In cases where a deletional or insertional mutation is 
responsible, mapping the mutation can easily be achieved through restriction enzyme digestion and 
differences in DNA fragment migration in agarose gels. In cases where a point mutation or a small 
deletion mutation occurs, sequencing of the viral genome or using marker transfer of genetic domains 
must be used to map the mutation. Thus, these studies emphasize the importance of the in vivo tumor 
environment for selecting novel oncolytic HSV strains that mediate improved survival in vivo. 
6. Engineered Mutations 
The serial passaging of many viruses has resulted in selection of novel mutations providing unique 
insights into the complexity of evasion of PKR by HSV vectors. The findings of these studies have 
helped investigators specifically engineer viruses with the goal of improving their anti-tumor activity 
and producing more effective vaccine vectors. Additionally, other strategies have been investigated 
which involve the engineering of novel viruses to enhance the oncolytic activity of 134.5 HSV 
oncolytic vectors. These are summarized in the following subsections. Viruses 2009, 1                                       
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6.1. R8309 
One strategy employed replacing the carboxyl terminus of the 134.5 gene, responsible for blocking 
host PKR-mediated protein shutoff, with the murine gene encoding myeloid differentiation gene 116 
(MyD116), which is homologous to this region   [13]. Both MyD116 and the hamster homologue 
GADD34, are primary response genes in hematopoiesis and expressed during growth arrest and DNA 
damage. The virus constructed with this substitution in the 134.5 gene, R8309, does not induce 
premature host protein shutoff in infected human cells  [13]. Treatment of human gliomas established 
intracranially in SCID mice with R8309 prolonged survival as compared to controls  [22]. 
6.2. G47 – engineering the US12 US11 mutation 
Tumor destruction is expected to be determined in part by the properties of the oncolytic virus used, 
but is also likely strongly influenced by viral-host interaction and induction of an immune response 
against the tumor. US12 gene expression from HSV-1 functions to inhibit transporter associated with 
antigen presentation (TAP) of MHC I. When deleted, MHC Class I expression from infected cells is 
increased. The G47 virus contains an engineered 47 gene deletion in a G207 vector  [37]. Like the 
second site mutants described above, it places US11 gene expression (normally a  or late gene) under 
the control of the immediate-early 47 promoter  [33].  The authors suggest the combination of early 
US11 expression (allowing for improved viral replication) along with increased MHC I presentation 
(allowing enhanced cytopathic effect) result in greater anti-tumor activity of G47 in various animal 
tumor models, including metastatic breast cancer to the brain  [38], prostate adenocarcinoma  [39], and 
schwannomas   [40]. These benefits were achieved without increasing the neurovirulence of the   
vector  [37]. 
6.3. Controlled expression of the 134.5 gene or tumor targeting of 134.5 containing HSV 
Deletion of the 134.5 neurovirulence gene allows the safe administration of oncolytic HSV to brain 
tumors without producing hemorrhagic encephalitis characteristic of wild-type HSV-1 infection. 
However, since this deletion also diminishes the replicative and cytotoxic abilities of the virus, groups 
have investigated the targeted expression of the 134.5 gene to replicating tumors. One method 
involves placing the 134.5 gene expression under the control of a tumor specific promoter or enhancer 
thereby limiting 134.5 gene expression in complementing tumor cells. One copy of the 134.5 gene 
was reintroduced under the control of the cellular B-myb promoter, which responds to E2F 
regulation  [41]. As expected, late viral protein synthesis was maintained after infection with this 
Myb34.5 virus, which also has a deletion of the ICP6 ribonucleotide reductase gene, and there was 
greater viral replication. Anti-tumor effect was increased relative to 134.5 HSV-1 in a murine model 
of liver metastasis  [42]. More importantly, the study suggests the potential of regulating 134.5 gene 
expression by promoters regulated by the cell-cycle to permit HSV-1 to demonstrate its efficacy within 
cycling tumor cells yet retaining an advantageous neurovirulence profile. Further development of the 
targeted expression of the 134.5 has led to the development of two other conditional expressing HSV 
recombinants that regulate 134.5 gene expression using nestin enhancers or musashi promoter (both Viruses 2009, 1                                       
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active in GBM tumors and CNS stem cells)  [43,44]. Another method is to limit HSV (134.5 +) viral 
entry to tumor cells. To achieve this, recombinant R5111 was created and replaces the HSV entry 
molecule gD with a tumor specific fusion entry molecule (gD-IL-13 R 2)  [45]. Cell culture studies 
show that R5111 replicate specifically in tumor  [46]. 
6.4. Chimeric HSV 
A different method hypothesized that transfer of the human cytomegalovirus (HCMV) PKR evasion 
genes TRS1 or IRS1 gene to a 134.5 virus (producing viruses C130 and C134, respectively) would 
improve viral replication and anti-glioma activity. The TRS1 and IRS1 protein products are HCMV’s 
tools for blocking the dsRNA-dependent PKR response pathway   [47,48]. These “chimeric” HSV 
vectors expressing HCMV genes improved late viral protein synthesis by preventing the shutdown of 
protein synthesis after viral infection. This attribute proffers the ability to replicate to wild-type levels 
in human malignant glioma cells in vitro. In vivo, C130 and C134 were found to be aneurovirulent 
with LD50 measurements from four to over six logs higher than that of wild-type HSV-1 (LD50 = 
6.8x10
5 for C130, >1x10
7 for C134)  [23]. Therefore, despite restoration of late viral protein synthesis 
and greater replication of progeny virus, expression of TRS1 and IRS1 did not restore wild-type 
neurovirulence. Indeed, incorporation of TRS1 and IRS1 into the attenuated 134.5 virus produced a 
more robust vector, permitting more efficient destruction of tumor cells and resulting in enhanced anti-
tumor activity. Improved survival was noted in two brain tumor models: a human malignant glioma in 
severe combined immune deficient (SCID) mice and a syngeneic immunocompetent murine 
neuroblastoma model   [23]. Both chimeric viruses demonstrated enhanced anti-glioma activity 
compared to their parent 134.5 virus, and performed superiorly at lower doses. A similar greater 
anti-tumor benefit was seen comparing the viruses against a murine neuroblastoma model [23]. These 
studies suggest that replication of oncolytic HSV-1 vectors in partially restrictive tumor cells due to 
anti-viral PKR responses can be significantly improved by encoding PKR-evasion genes from a related 
herpesvirus. 
7. Conclusions 
Viral protein synthesis is critical for efficient viral replication. As a consequence, HSV has evolved 
numerous genes involved in maintaining cellular functions necessary for viral replication. Despite the 
extensive viral control of the cellular environment, intrinsic intracellular defense systems are 
nevertheless active and can disrupt viral gene expression. Efforts over the last decade have translated 
some of the principal work involving HSV innate immune evasion toward development of HSV-1 viral 
vectors for use as both vaccine and anti-tumor therapy. Fundamental scientific research elucidating 
these viral mechanisms has made these clinical applications possible.  
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